Alterity Therapeutics (NASDAQ:ATHE) is now covered by analysts at Canaccord Genuity Group Inc.. They set a "speculative buy" rating on the stock.
Alterity Therapeutics to Present at the Bell Potter Healthcare Virtual Conference [Yahoo! Finance]
Alterity Therapeutics to Present at the Bell Potter Healthcare Virtual Conference
Alterity Therapeutics Presents Promising Impact of ATH434 on Orthostatic Hypotension and Disease Progression in MSA at the 36th International Symposium on the Autonomic Nervous System [Yahoo! Finance]
Alterity Therapeutics Presents Promising Impact of ATH434 on Orthostatic Hypotension and Disease Progression in MSA at the 36th International Symposium on the Autonomic Nervous System